News October 1, 2026MavriX Bio Announces FDA Rare Pediatric Disease Designation for Investigational MVX-220 for the Treatment of Angelman Syndrome (PR Newswire)September 22, 2026SK pharmteco and GEMMABio expand rare disease manufacturing collaboration following important spinal muscular atrophy (SMA) clinical trial milestone (GlobeNewswire)August 5, 20262 Philadelphia labs receive millions in federal funding to create treatments for rare genetic diseases in 5 years (WHYY News)July 10, 2026Feds award $43 million to Philly gene therapy research to advance treatments for rare diseases (The Philadelphia Inquirer)July 9, 2026ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases (ARPA-H)June 4, 2026Lilly Gateway Labs incubator in Center City gets its first tenant(Philadelphia Business Journal)October 7, 2025Jim Wilson's Gemma Bio spins out RareTx to scale gene therapy for ultra-orphan diseases(Philadelphia Business Journal)July 7, 2025Jim Wilson's Gemma Bio enters into its second international gene therapy partnership(Philadelphia Business Journal)July 5, 2025Abu Dhabi to partner with GEMMABio Therapeutics, advance gene therapies for children with spinal muscular atrophy(Aletihad)June 30, 2025'We can't waste money': Dr. James Wilson believes gene therapy needs a new business model(Philadelphia Business Journal)May 27, 2025Geneticist Jim Wilson left UPenn behind, but not his dream of curing rare genetic diseases(The Philadelphia Inquirer)January 27, 2025GEMMABio rakes in $34M raise, a huge boost to the Philly life sciences scene (Technical.ly)December 24, 2024UPenn gene therapy pioneer’s biotech gets $34 million in funding(The Philadelphia Inquirer)October 8, 2024Jim Wilson secures $100M for global approach aimed at reviving gene therapy field(Endpoints News)
